Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

被引：1
|
作者：
Oarbeascoa, Gillen [1 ]
Redondo, Sara [2 ]
Jose Moran-Jimenez, Maria [3 ]
Domingo, Amalia [1 ]
Munoz-Linares, Cristina [2 ]
Isabel Moreno-Carralero, Maria [4 ]
Maria Bellon, Jose [5 ]
del Campo Rincon, Juan Francisco [2 ]
Luis Diez-Martin, Jose [1 ,5 ,6 ]
Font, Patricia [1 ,5 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Hematol Dept, Madrid, Spain
[2] Hosp Univ Henares, Hematol Dept, Madrid, Spain
[3] Hosp 12 Octubre I 12, Inst Invest Sanitaria, Madrid, Spain
[4] Hosp 12 Octubre Imas12, Inst Invest Sanitaria, Madrid, Spain
[5] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[6] Univ Complutense Madrid, Dept Med, Madrid, Spain
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116992
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3085
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Roberto Castelli
    Riccardo Schiavon
    Valentina Rossi
    Giorgio Lambertenghi Deliliers
    Medical Oncology, 2018, 35
  • [22] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Castelli, Roberto
    Schiavon, Riccardo
    Rossi, Valentina
    Deliliers, Giorgio Lambertenghi
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [23] Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
    Castelli, Roberto
    Deliliers, Giorgio Lambertenghi
    Colombo, Riccardo
    Moreo, Guido
    Gallipoli, Paolo
    Pantaleo, Giuseppe
    ANNALS OF HEMATOLOGY, 2014, 93 (09) : 1523 - 1529
  • [24] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
    Ghaderi, Afshin
    Nodehi, Sayyed Reza Safaee
    Bakhtiari, Tahereh
    Aslani, Mona
    Aghazadeh, Zahra
    Matsuo, Hidenori
    Rehm, Bernd H. A.
    Cuzzocrea, Salvatore
    Mirshafiey, Abbas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 879 - 888
  • [25] Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)
    Fenaux, P
    SEMINARS IN ONCOLOGY, 2005, 32 (04) : S11 - S15
  • [26] Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes
    Tamburini, J.
    Elie, C.
    Park, S.
    Beyne-Rauzy, O.
    Gardembas, M.
    Berthou, C.
    Mahe, B.
    Sanhes, L.
    Stamatoullas, A.
    Vey, N.
    Aouba, A.
    Slama, B.
    Quesnel, B.
    Vekhoff, A.
    Sotto, J. J.
    Vassilief, D.
    Al-Nawakil, C.
    Fenaux, P.
    Dreyfus, F.
    Bouscary, D.
    LEUKEMIA RESEARCH, 2009, 33 (04) : 547 - 550
  • [27] Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
    Ma, Xiaomei
    Wang, Rong
    Galili, Naomi
    Mayne, Susan T.
    Wang, Sa A.
    Yu, Herbert
    Raza, Azra
    CANCER CAUSES & CONTROL, 2011, 22 (04) : 623 - 629
  • [28] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Fu, Alex Z.
    Maciejewski, Jaroslaw R.
    Golshayan, Ali-Reza
    Kalaycio, Matt E.
    Kaftan, Michael W.
    CANCER, 2007, 109 (06) : 1125 - 1132
  • [29] Use of steroids in the management of low-risk myelodysplastic syndromes with autoimmune features
    Fattizzo, Bruno
    Serpenti, Fabio
    Versino, Francesco
    Cassanello, Giulio
    Cro, Lilla M.
    Barbieri, Marzia
    Croci, Giorgio A.
    Revelli, Nicoletta
    Porta, Matteo G. Della
    Barcellini, Wilma
    BLOOD TRANSFUSION, 2023, 21 (05) : 452 - 460
  • [30] Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes
    R. Tehranchi
    Medical Oncology, 2006, 23 (1) : 37 - 49
12345